Latest News

WVU Cancer Institute Adopts Ryght AI Tools for Trial Matching and Enrollment

by BiopharmaTrend   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

West Virginia University (WVU) Cancer Institute has joined Ryght AI’s clinical trial site network, giving the academic cancer center access to tools designed to automate site feasibility and trial enrollment workflows. The partnership gives WVU Cancer Institute a position within Ryght’s expanding network of research institutions and contract research organizations using generative and agentic AI to support clinical operations.

#advertisement
AI in Drug Discovery Report 2025

Ryght AI, founded in 2023 by Simon Arkell and Alex Dickinson, had raised $3 million in seed funding in June to expand its platform, bringing total capital raised to over $9 million. The Laguna Beach–based company claims to have created digital twins for over 100,000 clinical trial sites globally—virtual models used by sponsors to simulate site capacity and protocol fit. Ryght's tools are intended to reduce trial activation timelines from 3–6 months to as little as three weeks.

See also: The Pivotal Role of AI in Clinical Trials: From Digital Twins to Synthetic Control Arms

WVU Cancer Institute, headquartered in Morgantown, is the only center in West Virginia offering bone marrow transplants, CAR-T cell therapy, photopheresis, gamma knife radiosurgery, and HIPEC, among other advanced oncology services. It operates a regional network of care centers, with larger sites providing surgery, infusion, radiation oncology, and medical oncology services, while smaller hospitals within the network focus on outpatient oncology and infusion. 

By joining Ryght’s platform, WVU Cancer Institute will use Ryght’s generative AI tools to evaluate both internal and external data to support operational decisions. The platform is intended to automate interactions between trial sites and sponsors and to simplify site selection and patient enrollment processes. These tools are designed to reduce manual workload and improve sponsor-site matching.

Ryght AI announced earlier this year that its network also includes Emory University, Keck School of Medicine at USC, The West Clinic, Medical College of Wisconsin, and CRO QPS Holdings. WVU indicated it will work with industry partners through this network to translate AI-supported research capabilities into community-level applications and patient access.

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email